Jason McNeese, MD
Gastroenterology · Ocean Springs, MSNPI 1659303303
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $21,400 of the $29,375 with a category attached, or 72.9%. Salix Pharmaceuticals, A Division Of Bausch Health US, LLC accounts for 85.1% of it on its own, with 24 other manufacturers making up the rest. Reporting peaked in 2019 at $24,884 and has fallen 95.4% since, to $1,138 in 2025. Among gastroenterology clinicians in MS with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 300 payments — averaging $97.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$25K
- AbbVie$2K
- Takeda Pharmaceuticals U.S.A., Inc.$418
- Olympus America Inc.$331
- Johnson & Johnson$329
- Celltrion USA Inc.$150
- plus $1K from 19 others
What the payments were for
- Speaking & faculty fees$21,40073%
- Travel & lodging$2,0417%
- Food & beverage$5,91920%
- Education$150%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 89 | $24,987 |
| AbbVie(2 entities) | 100 | $2,086 |
| Takeda Pharmaceuticals U.S.A., Inc. | 32 | $418 |
| Olympus America Inc. | 3 | $331 |
| Johnson & Johnson | 17 | $329 |
| Celltrion USA Inc. | 7 | $150 |
| Evoke Pharma, Inc. | 4 | $121 |
| Lilly USA, LLC | 6 | $115 |
| Phathom Pharmaceuticals, Inc. | 6 | $110 |
| Ipsen Biopharmaceuticals, Inc | 4 | $100 |
| Ardelyx, Inc. | 4 | $92 |
| Ironwood Pharmaceuticals, Inc | 5 | $79 |
| Redhill Biopharma Inc. | 4 | $78 |
| QOL Medical, LLC | 2 | $59 |
| Sanofi | 2 | $58 |
| Gilead | 3 | $57 |
| Pfizer | 2 | $35 |
| Mauna Kea Technologies, Inc. | 2 | $34 |
| Intercept Pharmaceuticals, Inc. | 2 | $32 |
| Organon | 1 | $26 |
| Capsovision, Inc. | 1 | $22 |
| Bristol Myers Squibb | 1 | $16 |
| Azurity Pharmaceuticals, Inc. | 1 | $15 |
| Daiichi Sankyo Inc. | 1 | $14 |
| AstraZeneca | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRULANCE$19,617
- XIFAXAN$4,001
- EVIS EXERA lll COLONOVIDEOSCOPE$141
- EVIS EXERA III GASTROINTESTINAL VIDEOSCOPE$141
- Rinvoq$125
- EVIS EXERA III COLONOVIDEOSCOPE$107
- Skyrizi$102
How this compares
$29,375 in reported general payments places this provider in the 90th percentile of 127 gastroenterology providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LinzessLinaclotide | 133 | $80,586 |
| TrulancePlecanatide | 16 | $11,675 |
| Sucralfate | 87 | $4,302 |
| Pantoprazole Sodium | 571 | $3,970 |
| Dicyclomine Hcl | 334 | $3,823 |
| Cholestyramine LightCholestyramine | 28 | $2,395 |
| Nadolol | 30 | $995 |
| Lactulose | 14 | $572 |
| Esomeprazole Magnesium | 20 | $480 |
| Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine | 20 | $407 |
| Omeprazole | 74 | $393 |
| Ondansetron OdtOndansetron | 17 | $302 |
| Amitriptyline Hcl | 59 | $192 |
| Azathioprine | 11 | $192 |
| Ondansetron Hcl | 34 | $178 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess | $2,086 | $80,586133 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance | $24,987 | $11,67516 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 127 gastroenterology providers in Mississippi.
Other gastroenterology in Ocean Springs
- Alfred McNairOcean Springs$16K
- Alva DillonOcean Springs$4K
- Wassem JuakiemBiloxi$519K
- Reed HoganFlowood$216K
- John PhillipsTupelo$150K
- Brian BorgJackson$68K
- Pegah Hosseini-CarrollJackson$62K
- Shou Jiang TangJackson$50K
- Vonda ReevesFlowood$39K
- Ernest WilliamsOxford$38K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.